Home
Focus & approach
Dare
Build
Criteria
Portfolio
Team & Partners
Team Investment Management
Advisory board
Partners
vacancies
News & Events
News
Media
Events
Impact & ESG
Impact & ESG
impact Committee
Contact
Home
Focus & approach
Dare
Build
Criteria
Portfolio
Team & Partners
Team Investment Management
Advisory board
Partners
vacancies
News & Events
News
Media
Events
Impact & ESG
Impact & ESG
impact Committee
Contact
News archive
Featured
Thuja is a proud supporter and active member of the EU Life Sciences ESG Knowledge Project, which has now released its 2025 questionnaire for investors
Meet Eline van Beest, Operational Partner at Thuja
Thuja's 2023 Impact & ESG Annual Report
Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome
We are delighted to share that Thuja led the extension of Tacalyx’s seed financing!
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
Meet Tyler Hayes, Principal at Thuja
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine
Thuja promotes Eleanor Price to Associate
Meet Aartie Nanda, office & communication manager at Thuja
Thuja Capital co-leads a €12M Seed investment in Artica Therapeutics.
Synerkine Pharma secures EUR 12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept
